Atlas Trials

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Clinical trial NCT03618238 · COMPLETED

Trial details

NCT number
NCT03618238
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Start date
2018-07-25
Primary completion
2021-04-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.